BioNTech SE (22UA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNTech SE (22UA) has a cash flow conversion efficiency ratio of -0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-421.00 Million ≈ $-492.19 Million USD) by net assets (€18.70 Billion ≈ $21.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is BioNTech SE's balance sheet to measure how much of total assets are equity-financed.
BioNTech SE - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BioNTech SE (22UA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
BioNTech SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amer Sports, Inc.
NYSE:AS
|
0.107x |
|
MKS Instruments Inc
NASDAQ:MKSI
|
0.019x |
|
Northern Star Resources Ltd
AU:NST
|
0.068x |
|
CHINA SHENHUA EN.A ADR/4
F:IKFC
|
N/A |
|
Incyte Corporation
NASDAQ:INCY
|
0.067x |
|
LyondellBasell Industries NV
NYSE:LYB
|
-0.026x |
|
Snap-On Inc
NYSE:SNA
|
0.045x |
|
MTN Group Ltd
JSE:MTN
|
0.255x |
Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2025)
The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of BioNTech SE.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.22 Billion ≈ $22.48 Billion |
€456.00 Million ≈ $533.11 Million |
0.024x | +121.68% |
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
€207.70 Million ≈ $242.82 Million |
0.011x | -95.97% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
€5.37 Billion ≈ $6.28 Billion |
0.265x | -60.81% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
€13.58 Billion ≈ $15.87 Billion |
0.677x | +805.01% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
€889.70 Million ≈ $1.04 Billion |
0.075x | +860.15% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
€-13.50 Million ≈ $-15.78 Million |
-0.010x | +97.55% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
€-198.50 Million ≈ $-232.07 Million |
-0.402x | -82.41% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
€-58.88 Million ≈ $-68.83 Million |
-0.221x | -120.22% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
€-52.56 Million ≈ $-61.45 Million |
1.090x | -- |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more